ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer
03 August 2020 - 9:17AM
ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage
immunology and oncology focused biopharmaceutical company
developing innovative treatments to transform the lives of
patients, today announced that Dr Kenneth Kobayashi has been
appointed Chief Medical Officer. Dr Kobayashi will be based in
California and will be responsible for the global clinical
development of ASLAN’s pipeline, including the lead program,
ASLAN004, an antibody that blocks the IL-13 receptor, which is
being developed for atopic dermatitis (AD).
Dr Kobayashi has more than 25 years of experience in drug
development, clinical practice and regulatory affairs as a
Dermatology expert. He most recently served as Senior Medical
Director at Dermira, a subsidiary of Eli Lilly, where he was
responsible for the development of lebrikizumab, a monoclonal
antibody for atopic dermatitis, and supported five Phase 3
registration studies together with preclinical and early clinical
development for two novel compounds.
Prior to joining Dermira, Dr Kobayashi was Clinical Development
Medical Director at Novartis, in the Immunology, Hepatology and
Dermatology Global Development Unit, where he supported the
development programs for anti-IL-17C and anti-IgE monoclonal
antibodies. He has also held senior and global leadership positions
at LEO Pharma and was an Associate Professor, and Chair and Chief
of the Division of Dermatology at the University of Ottawa and The
Ottawa Hospital.
Dr Carl Firth, Chief Executive Officer, ASLAN
Pharmaceuticals, said: “We are pleased to welcome Ken to
our team and look forward to working with him as we plan for the
late stage development of ASLAN004 in atopic dermatitis. He brings
strong industry expertise and relationships from working on other
novel biologics being developed for AD as well as his insights as a
trained dermatologist. Ken’s appointment is an important step for
ASLAN as we build our presence in the US in order to execute our
global Phase 2b program in 2021.”
Dr Ken Kobayashi, Chief Medical Officer, ASLAN
Pharmaceuticals, commented: “I am very excited to join
ASLAN and lead the global development of ASLAN004, a program I
believe has the potential to be best-in-disease for atopic
dermatitis and other indications. I am looking forward to
working closely with the team as we prepare for important clinical
data readouts later this year from the ongoing multiple ascending
dose study in AD and plan our move into additional
indications.”
Dr Kobayashi completed his residency in Dermatology at the
University of British Columbia and was a Chief Resident at the
National Defence Medical Centre, Ottawa. He is an Adjunct
Professor, Department of Medicine, at the University of Ottawa, and
a fellow of the Royal College of Physicians and Surgeons of Canada
and the American Academy of Dermatology.
Media and IR contacts
Emma ThompsonSpurwing CommunicationsTel: +65 6751
2021Email: ASLAN@spurwingcomms.com |
Robert UhlWestwicke PartnersTel: +1 858 356 5932
Email: robert.uhl@westwicke.com |
|
About ASLAN Pharmaceuticals ASLAN
Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage
immunology and oncology focused biopharmaceutical company
developing innovative treatments to transform the lives of
patients. Led by a senior management team with extensive experience
in global development and commercialisation, ASLAN has a clinical
portfolio comprised of a first in class monoclonal therapy,
ASLAN004, that is being developed in atopic dermatitis and other
immunology indications, and a small molecule inhibitor targeting
oncology. ASLAN’s partners include Almirall, Array BioPharma,
Bristol-Myers Squibb, and CSL. For additional information please
visit www.aslanpharma.com.
Forward looking statements
This release and the accompanying financial information, if any,
contains forward-looking statements. These statements are based on
the current beliefs and expectations of the management of ASLAN
Pharmaceuticals Limited and/or its affiliates (the "Company").
These forward-looking statements may include, but are not limited
to, statements regarding the Company’s business strategy, the
Company’s plans to develop and commercialise its product
candidates, the safety and efficacy of the Company’s product
candidates, the Company’s plans and expected timing with respect to
regulatory filings and approvals, and the size and growth potential
of the markets for the Company’s product candidates. The Company’s
estimates, projections and other forward-looking statements are
based on management's current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and
inherently involve significant known and unknown risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation the risk factors described in the
Company’s U.S. Securities and Exchange Commission filings and
reports (Commission File No. 001-38475), including the Company’s
Form 20-F filed with the U.S. Securities and Exchange Commission
(the “SEC”) on April 16, 2020. All statements other than statements
of historical fact are forward-looking statements.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024